Immunotherapy in Melanoma | Specialty

Dr. Postow on Nivolumab Combined With Ipilimumab in Melanoma

March 31st 2016

Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.

TILs Advancing as Melanoma Immunotherapy Option

March 31st 2016

After nearly 30 years of research, tumor-infiltrating lymphocyte technology is being investigated as a means of producing personalized immunotherapy for patients with metastatic melanoma in a small clinical trial that may help open the door for broader application in other solid tumor types.

The New Front Line in Melanoma: Immunotherapy or Targeted Agents?

March 16th 2016

The bounty of choices is good news for patients with melanoma, several key questions have emerged: Should immunotherapy or targeted agents be the first-line choice for metastatic melanoma?

OPTiM Follow-up Shows Improved CR Rate With T-VEC in Melanoma

March 7th 2016

Robert Andtbacka, MD, explains the goals of the retrospective analysis of the OPTiM study, the significance of its results, and the future for T-VEC in melanoma.

Expert Shares Challenges, Considerations When Using Immunotherapies in Melanoma

March 7th 2016

Michael Postow, MD, discusses the benefits and challenges of combination regimens versus single-agent regimens, the possibility of targeted agents with immunotherapies, and the management of toxicities with immunotherapies.

Will Immunotherapy or Targeted Therapy Take the Lead in Melanoma?

March 5th 2016

Michael Atkins, MD, discusses his views on the potential of immunotherapy versus targeted therapy in melanoma, what research has shown so far, and what could be on horizon for both classes of drugs going forward.

Dr. Tara C. Gangadhar on Atypical Responses with Immunotherapies in Melanoma

March 3rd 2016

Tara C. Mitchell, MD, assistant professor of Medicine at the Hospital of the University of Pennsylvania, Perelman School of Medicine, discusses atypical responses with immunotherapies in melanoma.

Beyond BRAF: Emerging Agents Aim at Other Melanoma Targets

March 2nd 2016

Jason Luke, MD, discusses how molecular subtyping has expanded targeted therapy approaches beyond BRAF inhibition, current trials investigating emerging targeted agents, and what can be expected in this space going forward.

Dr. Randal Weber on Future Treatment Approaches for Patients With Melanoma

March 1st 2016

Randal S. Weber, MD, FACS, professor, department chair, John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses future treatment approaches for patients with melanoma.

Weber Compares BRAF/MEK, Immunotherapy Combos in Melanoma

March 1st 2016

Jeffrey S. Weber, MD, PhD, discusses recent long-term follow-up data of dabrafenib and trametinib in melanoma that may shed some light on sequencing questions for BRAF-mutated patients.

Novel Checkpoints Offer Hope After Standard Melanoma Immunotherapies Fail

February 29th 2016

Omid Hamid, MD, discusses promising agents and combinations that offer hope to patients with melanoma for whom standard checkpoint agents and/or targeted therapies are not an option.

Dr. Andtbacka on Ongoing Trials With Oncolytic Immunotherapies in Melanoma

February 9th 2016

Robert Andtbacka, MD, associate professor, Division of Surgical Oncology, Department of Surgery, University of Utah School of Medicine, discusses ongoing clinical trials investigating oncolytic immunotherapies as a treatment for melanoma.

Melanoma Brings Immunotherapy to the Forefront, But Challenges Remain

February 9th 2016

Jeffrey S. Weber, MD, PhD, discusses the role that melanoma specialists can play in educating other oncologists, immunotherapy use for BRAF-mutated patients with melanoma, and how the use of chemotherapy may evolve as immunotherapies take the forefront.

Immunotherapy Shows Potential in Rare Melanoma Subtype

February 9th 2016

Richard Joseph, MD, discusses the challenges of treating mucosal melanoma and what oncologists need to know prior to using immunotherapies for the treatment of both mucosal and cutaneous melanomas.

Expert Discusses Next Steps With T-VEC in Melanoma

February 8th 2016

Howard L. Kaufman, MD, discusses remaining questions regarding T-VEC, the impact of the FDA approval, and its future potential.

Combining Nivolumab With Radiation Shows Promise in Melanoma Patients With Brain Mets

February 2nd 2016

Combining nivolumab (Opdivo) with radiation therapy may provide better disease control and prolong overall survival in patients with melanoma whose disease has metastasized to the brain, compared with standard current treatment.

Dr. Kirkwood on Annual Skin Screening for Melanoma

February 2nd 2016

John M. Kirkwood, MD, Usher Professor of Medicine, Dermatology & Translational Science, director, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, University of Pittsburgh, discusses a recent study that trained general practitioners and nurses to conduct annual skin examinations.

Medical World News: Precision Medicine in Oncology

February 2nd 2016

Expression of the apoptosis regulator protein BIM could help predict response to PD-1 blockade in patients with melanoma.

Wolchok on Impact of Nivolumab's Expanded Approval in Melanoma

February 2nd 2016

Jedd D. Wolchok, MD, discusses the implications of the expanded FDA approval of nivolumab, and the potential for the PD-1 inhibitor as both a single agent and as part of a combination regimen in advanced melanoma

FDA Approval in Myeloma, Expanded Approval in Melanoma, GI Cancer Symposium Highlights, and More

January 28th 2016